Skip to main content

Pharmacokinetic Differences

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

NeuroDawn Pharmaceutical
1 program
1
Y-3 for injection(40mg)Phase 11 trial
Active Trials
NCT07055412Not Yet Recruiting24Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2025
2026
NeuroDawn PharmaceuticalY-3 for injection(40mg)

Clinical Trials (1)

Total enrollment: 24 patients across 1 trials

NCT07055412NeuroDawn PharmaceuticalY-3 for injection(40mg)

Y-3 for Injection in Patients With Hepatic Insufficiency and Healthy Subjects

Start: Jul 2025Est. completion: Dec 202524 patients
Phase 1Not Yet Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.